Trump Urges Exxon, Chevron to Cut Gas Prices After Record Oil Profits 
DBS Raises 2025 Outlook After Record Q2 Profit Driven by Wealth Management 
Infineon Raises 2026 Revenue Outlook as AI Data Center Demand Fuels Record Quarterly Sales 
SK Hynix Bonus Dispute Deepens as Union Rejects Stock-Based Payout Proposal 
Heineken H1 Operating Profit Meets Forecast as Beer Volumes Beat Expectations 
Samsung, SK Hynix Test AMEC Chipmaking Tools for China Backup Plan 
DoorDash Q2 Revenue Jumps 36% as Orders and DashPass Growth Drive Results 
Siemens Energy Q3 Profit Beats Forecast as AI-Driven Power Demand Fuels Growth 
Meta AI Model Exploits Security Flaw During Cybersecurity Test, Raising AI Safety Concerns 
Bayer Q2 Earnings Beat Forecasts as Crop Science Boosts Results, Debt Outlook Improves 
HSBC H1 Profit Jumps 23%, Announces $1 Billion Share Buyback and Reaffirms 2028 Targets 
Boeing Stock Jumps as FAA Certifies 737 MAX-7 After Years of Regulatory Review 
Palantir Stock Soars as AI Demand Drives Strong Q2 Earnings and Higher 2026 Outlook 
Apple Restores Telegram to App Store After Content Policy Violation 
DeepSeek to Raise AI API Prices as Demand for New Models Surges 
BHP Port Hedland Strike Set to Proceed as Wage Talks Continue 
SpaceX Targets Starship Flight 14 With First V3 Starlink Satellite Launch 
GAITHERSBURG, Md., March 22, 2018 -- Altimmune, Inc. (Nasdaq:ALT), a clinical-stage immunotherapeutics company, announced today that Bill Enright, President and Chief Executive Officer, will provide a corporate overview at H.C. Wainwright Global Life Sciences Conference, being held April 8-10 in Monte Carlo, Monaco.
| Presentation Details - H.C. Wainwright Global Life Sciences Conference | ||
| Date: | Tuesday, April 10, 2018 | |
| Time: | 9:25am Eastern Time/3:25pm Central European Time | |
| Location: | LeMeridien Beach Plaza Hotel, Monte Carlo, Salon Atlantique-Meridional | |
| Webcast: | http://wsw.com/webcast/hcw2/alt/ | |
About Altimmune
Altimmune is a clinical-stage immunotherapeutics company focused on the development of products to stimulate robust and durable immune responses for the prevention and treatment of disease including NasoVAX, a Phase 2 seasonal influenza vaccine candidate, and HepTcell, a Phase 1 immunotherapeutic candidate for the potential cure of chronic hepatitis B. The company also has two United States government funded, next-generation anthrax vaccine candidates that are intended to improve protection and safety while having favorable dosage and storage requirements compared to other anthrax vaccines.
Contacts:
Bill Enright
President and CEO
Phone: 240-654-1450
[email protected]
Ashley Robinson
LifeSci Advisors, LLC
617-535-7742
[email protected]
